Navigation Links
Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine
Date:9/8/2009

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza.

"We thank the NIH for funding the further safety and efficacy tests, which, along with our previous successful animal studies, will pave the way towards clinical trials," said Principal Investigator Sean Tucker, Ph.D. The grant runs for a period of three years.

Vaxart has developed a proprietary approach to vaccine creation that, the company believes, will enable it to produce a portfolio of oral-delivery vaccines easily and quickly.

Central to Vaxart's approach is its unique adjuvant, the vaccine component that enhances immune responses. Vaxart uses an adjuvant that works through a "toll-like receptor" (TLR). TLR agents have been widely applied in vaccines and are well accepted as effective immune stimulators. Vaxart's approach employs TLR3 - the only TLR known to be fully active in the gastrointestinal tract - to stimulate a potent immune response when the vaccine is given in a pill instead of being injected.

The second advantage of the Vaxart approach is the ability to use the same vector, or delivery vehicle, across all vaccines. Usually, each vaccine requires a different vehicle, because people who have been vaccinated build antibodies against the vehicle. Later vaccinations using the same vehicle are less effective, as the body attacks the vehicle instead of the disease target. Vaxart has overcome this obstacle and has demonstrated strong immune responses against multiple targets following a series of oral vaccines. Vaxart believes it will be able to produce new vaccines through a standardized low-cost process, with low regulatory risk because data from one vaccine will help establish the safety of others.

The Vaxart Avian Flu Vaccine Program

The recent emergence of pandemic H1N1 flu has underlined the importance of being prepared for pandemic illnesses. Avian flu is an ideal first test for Vaxart's technology, due to its capability to quickly protect people against new threats. In studies completed in 2008, the vaccine successfully protected large animals against death from Avian flu infection.

About Vaxart

Vaxart is a San Francisco biotechnology company developing oral-delivery vaccines. The vaccines incorporate a proprietary adjuvant that boosts the immune response, enabling them to be effective when swallowed in a pill or capsule. Moving forward, Vaxart intends to develop next-generation, oral alternatives to existing vaccines with proven market potential. For more information, visit www.vaxart.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Sean Tucker, Ph.D.

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=88198

    CONTACT:    Michele Parisi
                925/429-1850
                ir-pr@vaxart.com


'/>"/>
SOURCE Vaxart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
3. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
4. PartsSource Awarded US Patent for PartsFinder(TM) Application
5. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
6. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
7. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
8. UMASS Medical School awarded National Childrens Study contract
9. beBetter Awarded WV Quitline Contract
10. Henricksen Awarded 2007 Distinguished Veterinary Staff Award
11. Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... IN (PRWEB) , ... February 08, 2016 , ... ... the Indianapolis, IN metro area, has selected the latest beneficiary of their ongoing ... organization dedicated to preventing bullying in area schools. Donations are now being accepted ...
(Date:2/8/2016)... ... 2016 , ... Remember the old saying “rub some dirt on it”? Perhaps ... of “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet ... , A former motivational speaker, Perry A~ has since dedicated her life to learning ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data ... of type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D ... change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all ... Day. National Wear Red Day is the first Friday each February and a ... stroke cause 1 in 3 deaths among women each year – more than all ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... DIEGO , Feb. 8, 2016  Neurocrine Biosciences, ... Company will report its fourth quarter and year-end 2015 ... 11, 2016.  Neurocrine will then host a live conference ... provide a Company update Thursday afternoon, February 11, 2016 ... http://www.neurocrine.com . --> http://www.neurocrine.com . ...
(Date:2/8/2016)... --> --> ... Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, ... Ophthalmology, Gynecology) - Global Forecasts to 2020", published by ... forecast period of 2015 to 2020. The market is ... of 10.5% from 2015 to 2020. Browse ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
Breaking Medicine Technology: